NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
0.5702
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for NovaBay Pharmaceuticals stock has a target of 0.85, which predicts an increase of 49.07% from the current stock price of 0.57.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for NovaBay Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $8 → $0.85 | Strong Buy | Maintains | $8 → $0.85 | +49.07% | Nov 11, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5,206 → $4,900 | Strong Buy | Maintains | $5,206 → $4,900 | +859,247.60% | May 20, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2018 |
| Roth Capital | Roth Capital | Strong Buy Initiates $193 | Strong Buy | Initiates | $193 | +33,660.08% | Jun 5, 2017 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $68,906 | Strong Buy | Initiates | $68,906 | +12,084,475.59% | Mar 6, 2013 |
Financial Forecast
Revenue This Year
12.12M
from 9.78M
Increased by 23.91%
Revenue Next Year
16.00M
from 12.12M
Increased by 32.05%
EPS This Year
-0.87
from -2.53
EPS Next Year
-0.38
from -0.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 12.6M | 16.6M |
| Avg | 12.1M | 16.0M |
| Low | 11.8M | 15.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 28.8% | 37.3% |
| Avg | 23.9% | 32.0% |
| Low | 20.2% | 28.1% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.90 | -0.40 |
| Avg | -0.87 | -0.38 |
| Low | -0.84 | -0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.